Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Post-Hurricane Distress Scale (PHDS): A Novel Tool for First Responders and Disaster Researchers.

Carl Y, Ortiz ER, Cintrón M, Vega A, Font C, Stukova M, Blundell A, Gutierréz AN, Burgos RF.

Disaster Med Public Health Prep. 2019 Feb;13(1):82-89. doi: 10.1017/dmp.2019.12.

PMID:
30841955
2.

Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico.

Zarei S, Eggert J, Franqui-Dominguez L, Carl Y, Boria F, Stukova M, Avila A, Rubi C, Chinea A.

Surg Neurol Int. 2018 Dec 3;9:242. doi: 10.4103/sni.sni_224_18. eCollection 2018. Review.

3.

Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.

Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Stukova M, Buzitskaya Z, Кulmagambetov I, Davlyatshin T, Khairullin B.

Hum Vaccin Immunother. 2018 Mar 4;14(3):609-614. doi: 10.1080/21645515.2017.1387345. Epub 2017 Dec 12.

4.

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase.

Kuznetsova I, Arnold T, Aschacher T, Schwager C, Hegedus B, Garay T, Stukova M, Pisareva M, Pleschka S, Bergmann M, Egorov A.

Mol Ther Oncolytics. 2017 Sep 8;7:37-44. doi: 10.1016/j.omto.2017.09.002. eCollection 2017 Dec 15.

5.

Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.

Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Abitay R, Nurpeisova A, Sagymbay A, Koshemetov Z, Stukova M, Buzitskaya Z, Кulmagambetov I, Karabayeva D, Davlyatshin T, Khairullin B.

J Med Virol. 2018 Jan;90(1):41-49. doi: 10.1002/jmv.24922. Epub 2017 Sep 25.

PMID:
28842994
6.

A novel preservative-free seasonal influenza vaccine safety and immune response study in the frame of preclinical research.

Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Nurpeisova A, Sagymbay A, Abitay R, Stukova M, Sansyzbay A, Khairullin B.

J Med Virol. 2017 Jul;89(7):1168-1173. doi: 10.1002/jmv.24771. Epub 2017 Mar 28.

PMID:
28160490
7.

Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.

Rudenko L, Naykhin A, Donina S, Korenkov D, Petukhova G, Isakova-Sivak I, Losev I, Stukova M, Erofeeva M, Nikiforova A, Power M, Flores J.

Hum Vaccin Immunother. 2015;11(12):2839-48. doi: 10.1080/21645515.2015.1069931.

8.

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

Rudenko L, Isakova-Sivak I, Naykhin A, Kiseleva I, Stukova M, Erofeeva M, Korenkov D, Matyushenko V, Sparrow E, Kieny MP.

Lancet Infect Dis. 2016 Mar;16(3):303-10. doi: 10.1016/S1473-3099(15)00378-3. Epub 2015 Dec 8.

9.

Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.

Rudenko L, Kiseleva I, Stukova M, Erofeeva M, Naykhin A, Donina S, Larionova N, Pisareva M, Krivitskaya V, Flores J; Russian LAIV Trial Study Group.

Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019. Epub 2015 Aug 19.

PMID:
26296497
10.

A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice.

Kittel C, Wressnigg N, Shurygina AP, Wolschek M, Stukova M, Romanovskaya-Romanko E, Romanova J, Kiselev O, Muster T, Egorov A.

Arch Virol. 2015 Oct;160(10):2525-34. doi: 10.1007/s00705-015-2525-9. Epub 2015 Jul 28.

PMID:
26215439
11.

Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.

Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM.

J Inorg Biochem. 2015 Aug;149:45-8. doi: 10.1016/j.jinorgbio.2015.05.003. Epub 2015 May 14.

12.

H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.

Isakova-Sivak I, Stukova M, Erofeeva M, Naykhin A, Donina S, Petukhova G, Kuznetsova V, Kiseleva I, Smolonogina T, Dubrovina I, Pisareva M, Nikiforova A, Power M, Flores J, Rudenko L.

Hum Vaccin Immunother. 2015;11(4):970-82. doi: 10.1080/21645515.2015.1010859.

13.

Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, Buzitskaya Z, Isakova-Sivak I, Kuznetsova S, Larionova N, Desheva J, Dubrovina I, Nikiforova A, Victor JC, Neuzil K, Flores J, Tsvetnitsky V, Kiselev O.

PLoS One. 2014 Feb 12;9(2):e87962. doi: 10.1371/journal.pone.0087962. eCollection 2014.

14.

Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector.

Kuznetsova I, Shurygina AP, Wolf B, Wolschek M, Enzmann F, Sansyzbay A, Khairullin B, Sandybayev N, Stukova M, Kiselev O, Egorov A, Bergmann M.

J Gen Virol. 2014 Feb;95(Pt 2):337-49. doi: 10.1099/vir.0.056036-0. Epub 2013 Nov 12.

PMID:
24222196
15.

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.

Clin Vaccine Immunol. 2013 Aug;20(8):1314-9. doi: 10.1128/CVI.00096-13. Epub 2013 Jun 26.

16.

[Genetic diversity and molecular evolution of the influenza A viruses in Russia during 2006-2012].

Grudinin MP, Komissarov AB, Pisareva MM, Stukova MA, Buzitskaia ZhV, Paiankova AA, Elpaeva EA, Zadonskaia AV, Ivanov IuV, Kiselev OI.

Vopr Virusol. 2012 Nov-Dec;57(6):37-42. Russian.

PMID:
23477253
17.

[Pathogenic aspects of influenza during the epidemics caused by A/H1N1v virus in 2009-2010 according autopsy data].

Tsinzerling VA, Vorob'ev SL, Zarubaev VV, Beliavskaia SV, Esaulenko EV, Grigor'eva IV, Dedov VA, Grudinin MP, Buzitskaia ZhV, Pisareva MM, Prochukhanova AR, Stukova MA, Azarenok AA, Zhilinskaia IN.

Arkh Patol. 2011 Nov-Dec;73(6):21-5. Russian.

PMID:
22379895
18.

[Prevention of tuberculosis: current approaches to development of vaccines].

Stukova MA, Zabolotnykh NV, Vinogradova TI, Gergert VIa, Apt AS, Kaprel'iants AS, Erokhin VV, Iablonskiĭ PK, Kiselev OI.

Vestn Ross Akad Med Nauk. 2012;(11):45-52. Review. Russian.

PMID:
23457981
19.

[The 2009 pandemic influenza in Russia. I. Diagnosis and molecular biological characteristics of the virus].

Kiselev OI, Komissarov AB, Stukova MA, Buzitskaia ZhV, Pisareva MM, Elpaeva EA, Danilenko DM, Konovalova NI, Gudkova TM, Grigor'eva VA, Smirnova TS, Slita AV, Romanovskaia-Roman'ko EA, Tsybalova LM, Sominina AA, Eropkin MIu, Grudinin MP.

Vopr Virusol. 2011 Jan-Feb;56(1):17-21. Russian.

PMID:
21427949
20.

[Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1].

Mironov AN, Bushmenkov DS, Dyldina NV, Romanova AA, Tsaan AA, Kiselev OI, Erofeeva MK, Stukova MA.

Zh Mikrobiol Epidemiol Immunobiol. 2010 May-Jun;(3):32-5. Russian.

PMID:
20737683
21.

[Clinical trial of new inactivated influenza vaccine "Grifor"].

Zverev VV, Kiselev OI, Korovkin SA, Mironov AN, Mel'nikov SIa, Mikhaĭlova NA, Kostinov MP, Erofeeva MK, Solomina AA, Dyldina NV, Zhirova SN, Stukova MA.

Zh Mikrobiol Epidemiol Immunobiol. 2009 Mar-Apr;(2):35-40. Russian.

PMID:
19459475
22.

[The effectiveness of influenza vectors expressing the protective mycobacterial antigen ESAT-6 in the complex therapy of generalized tuberculosis in mice].

Zabolotnykh NV, Vinogradova TI, Stukova MA, Vasil'eva SN, Vitovskaia ML, Egorov AIu.

Probl Tuberk Bolezn Legk. 2008;(12):30-4. Russian.

PMID:
19230185
23.

[Comparative clinical trial of vaccines against avian influenza].

Zverev VV, Katlinskiĭ AV, Kostinov MP, Zhirova SN, Erofeeva MK, Stukova MA, Korovkin SA, Mel'nikov SIa, Semchenko AV, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6. Russian.

PMID:
17672124
24.

Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, Vinogradova T, Katinger H, Kiselev O, Egorov A.

Clin Vaccine Immunol. 2006 Aug;13(8):898-904.

25.

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein.

Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, Vinogradova TI, Katinger H, Kiselev OI, Egorov A.

Tuberculosis (Edinb). 2006 May-Jul;86(3-4):236-46.

PMID:
16677861
26.

Live cold-adapted influenza A vaccine produced in Vero cell line.

Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A.

Virus Res. 2004 Jul;103(1-2):187-93.

PMID:
15163508
27.

[Quantitative competitive PCR--diagnostic method for monitoring cytomegalovirus infection and antiviral therapy].

Vinogradskaia GR, Drabkina MG, Stukova MA, Kiselev OI, Lantsov VA.

Mol Biol (Mosk). 1999 Sep-Oct;33(5):898-904. Russian. No abstract available.

PMID:
10579196
28.

[The molecular mechanism of the action of antiviral preparations in the adamantane series].

Kiselev OI, Blinov VM, Kozeletskaia KN, Il'enko VI, Platonov VG, Chupakhin ON, Stukova MA, Karginov VA.

Vestn Ross Akad Med Nauk. 1993;(3):10-5. Russian.

PMID:
7687902
29.

[Method of determination of the content of gramicidin C in alcoholic solutions by means of measuring optical activity].

Stukova MS, Fomenko GI.

Antibiotiki. 1970 Jan;15(1):84-5. Russian. No abstract available.

PMID:
5442478

Supplemental Content

Loading ...
Support Center